~~<i id='ADD29064C2'><strike id='ADD29064C2'><tt id='ADD29064C2'><pre id='ADD29064C2'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

entertainment

author：knowledge 2025-09-05 11:24:13 - browse：3

Alkermes shareholders voted Thursday to re-elect all of the drugmaker’s current directors, ending an acrimonious proxy fight with hedge fund Sarissa Capital Management, which had sought to seat three directors on the board.

At the company’s annual meeting, shareholders voted in favor of Alkermes’ proposal to retain all seven of the director nominees to the 11-person board.

The outcome is a setback for Sarissa, which owns 8.5% of Alkermes and is run by activist investor Alex Denner. Sarissa has accused Alkermes executives of mismanaging the business and destroying shareholder value.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Device maker Teleflex to acquire urology company for $600M

hotspot

focus

entertainment

focus

leisure time

MarkLennihan/APEarlyintheCovid-19pandemic,beforewehadvaccinesandeffectivemedicalprocedures,theonlywa

WSS

Why drug prescriptions should include diagnoses

What to watch for from Zogenix and Amicus clinical trials

Ask STAT: What do you want to know about ChatGPT in medicine?

Russian fighter jet damages US Reaper drone with flare over Syria: Officials

In areas with more Black doctors, Black people live longer

Democrats decry new health bill for going easy on private equity

hotspot

entertainment

hotspot

Bright Health sells Medicare Advantage business to Molina

With FDA staff opposed to Sarepta therapy, top official intervened

Heart attack and stroke risk calculators need revising

New lawsuit accuses health insurer Cigna of denying claims in bulk

United colonoscopy coverage change 'may cost lives,' doctors say

The story of mRNA: From a loose idea to a tool that may help curb Covid

Bright Health sells Medicare Advantage business to Molina

Biogen says it will cut costs by $700 million, slash 1,000 jobs

23andMe had bad news about my health. I wish a person had delivered it

UHS says company favors patients whose insurance pays more

focus

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

In the gardens at Boston Children's Hospital, families find sanctuary

WATCH: Why do fingernails fall off when they're damaged?

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

New guidelines on severe brain injury complicate already difficult decisions

Biden warns of ‘dark winter’ during final presidental debate

entertainment

focus

focus

leisure time